The company said it would use the funding in part to expand its commercial teams in the US and China, as well as to pursue Chinese regulatory approvals.
The firm will use funds from the round, which consists of $85 million in equity securities and a $50 million credit facility, to expand global sales and production.
The joint venture will further develop, manufacture, and distribute LevitasBio's magnetic levitation-based cell separation and purification platform in China.